The diffuse injury to peripheral nerves (diabetic neuropathy) is exceptionally common in type 1 diabetes, but there is a lack of an objective surrogate marker to identify early subclinical stages when treatments might be most effective, prior to late-stage progression to troublesome and costly foot infection, ulceration, and limb amputation. In contrast to the ability to objectively measure disease-specific surrogate markers for retinopathy and nephropathy, this lack of a diabetic neuropathy surrogate marker has seriously impeded the development of specific interventions in clinical research trials. Representing 5 independent research groups that have together created a consortium of investigators dedicated to the development of a surrogate marker for early diabetic neuropathy, we have focused on using the eye as a window to non-invasively image by a method of in-vivo corneal confocal microscopy (CCM) the small nerve fibres that innervate the cornea. We have demonstrated that changes in these nerve fibre endings occur early in the development of neuropathy, reflect well the changes seen in other peripheral nerves by invasive skin biopsy evaluation, and that their measurement is feasible and reproducible. As a multinational consortium, we have the benefit in this proposal of pooling multiple cohorts to apply the most valid study methods in biomarker development. First, we aim to determine in the analysis of an existing pooled dataset of 516 type 1 and 524 type 2 diabetes subjects the exact levels of CCM measurement that can identify the presence of diabetic neuropathy. Secondly, we propose over three years to re- examine at least 70% of this cohort, which will provide 5- to 7-year follow-up data to determine which type and level of CCM measurement can predict the future onset of neuropathy, as well as its progression in those who had neuropathy at baseline. Finally, we will evaluate the role of time- and cost-saving automated image analysis software. By virtue of large sample size from data pooling, we are uniquely afforded the methodological power to confirm our objectives by way of separate derivation and validation analysis sets. Through a unique and unprecedented multinational pooled dataset approach for diabetic neuropathy, this work will derive and validate specific CCM parameter thresholds for the identification of neuropathy, and - more importantly - the identification of individuals at future risk. These results will permit application in clinical practice and intervention trials for neuropathy risk stratification. Evaluaion of automated image analysis will influence likelihood of successful knowledge translation of this surrogate biomarker into clinical practice - in which the procedure could be harmonized with annual retinal examinations - and into intervention trials.

Public Health Relevance

Though diabetic neuropathy and the management of its complications (pain, infection, ulceration, limb amputation) represent a major limitation to the quality of life of those with type 1 diabetes and a major health economic burden, there is a fundamental need to establish an objective marker that can accurately diagnose, predict onset, and assess progression of neuropathy. We have a strong foundation to hypothesize that the measurement of corneal nerve morphology parameters using in-vivo corneal confocal microscopy (CCM), by virtue of non-invasive direct nerve fiber visualization that could be harmonized with the annual eye examinations that are part of current clinical practice, represents an accurate ocular biomarker of diabetic neuropathy in patients with type 1 and type 2 diabetes. Results of our pooled, multinational longitudinal datasets will unequivocally determine the role of CCM as a method to determine future risk of neuropathy to stratify patients in clinical practice and for the evaluation of putative interventions in clinical trials, which fro a public health perspective may provide a broadly applicable means for disease identification and prognosis in clinical practice and may provide a valid biomarker for use in the clinical trials designed to identify disease-modifying interventions.

National Institute of Health (NIH)
Type 1 Diabetes Targeted Research Award (DP3)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Jones, Teresa L Z
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
MT Sinai Hosp-Samuel Lunenfeld Research Institute
Zip Code
M5 3L9